Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

You may not qualify if:

• Concurrent chemotherapy drugs, anti-cancer therapy or anti-neoplastic hormonal therapy, or radiotherapy
• Prior receipt of survivin-based vaccines/therapy, immune checkpoint inhibitors, IDO inhibitor, or cell-based therapy
• Non-epithelial tumor origin of the ovary, fallopian tube, or peritoneum
• Clinical ascites
• Concurrent second malignancy other than basal or squamous cell skin cancer, cervical carcinoma in situ, or Stage I or II caner in complete remission
• GI condition that might limit absorption of oral agents
• Recent history of thyroiditis
• History of autoimmune disease requiring treatment within the last two years (except paraneoplastic syndrome, vitiligo, or diabetes)
• History of bowel obstruction related to the disease
• Presence of a serious acute infection or chronic infection
• Uncontrolled concurrent illness or history of significant cardiac or pulmonary disfunction
• Myocardial infarction or cerebrovascular event within past 6 months
• Known central nervous system (CNS) or leptomeningeal metastasis (brain metastases)
• Clinically significant illness or major surgery within past 28 days or anticipated need for major surgery during study treatment
• Ongoing treatment with steroid therapy or other immunosuppressive
• +3 more criteria